Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.
Key facts
- Who runs it
- Salome Kristensen
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 198 people enrolled
- Started
- 1 Aug 2023
- Ended
- 1 Sept 2025
- Type of study
- Observational
- Record updated
- 30 April 2026
Who can take part
- Age
- 50 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Men or women aged 50 to 85 years
- Are diagnosed with GCA or PMR
- Diagnosis is established by or confirmed by a rheumatologist (clinical expert opinion)
- Speak and understand Danish
- Are able to give signed and dated informed consent
Who cannot take part
- None
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to expand the knowledge about development and aggreviation of diabetes mellitus in patients with giant cell arthritis and polymyalgia rheumatica.
Read full original descriptionShow less
The main questions it aims to answer are:
* To identify the risk of comorbidities, especially diabetes, in patients with giant cell arthritis and polymyalgia rheumatica, treated with glucocorticoids in combination with or without interleukin-6 inhibitor. * To identify clinical outcomes and biomarkers as potential predictors for development or aggregation of already existing diabetes mellitus in patients with giant cell arthritis or polymyalgia rheumatica using machine learning prediction.
Participants will be followed at their respective rheumatology clinic, and will be asked to deliver blood samples at predefined visits.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 30 April 2026